Objective To evaluate marijuana use by adolescents and young adults with inflammatory bowel disease (IBD). Study design This descriptive cross-sectional study of patients seen between December 2015 through June 2017 at Children's Hospital Colorado for IBD enrolled patients 13-23 years of age, independent of marijuana use status. Information obtained consisted of chart review, electronic and interview self-report, and serum cannabinoid levels. Marijuana ever-users were compared with never-users for clinical characteristics and perceptions of risk with use; users provided information on routes, patterns, motivations, and perceived benefits and problems with use.
F orty-six states have approved medical marijuana and 8 states have laws allowing possession and consumption for recreational use. Inflammatory bowel disease (IBD, Crohn's disease, or ulcerative colitis) is an indication for access to medical marijuana in multiple states. 1 Marijuana (cannabis) is a biotic compound that contains multiple active cannabinoids including delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD). 2 The National Academy of Sciences has concluded that, in adults, marijuana is effective for chemotherapy-related nausea and vomiting, and may improve chronic pain as well as multiple sclerosis-related spasticity. 2 Patients and families have advocated using marijuana for the treatment of medical conditions and ask care providers about it for treating their IBD. 3, 4 Emerging understanding of the endocannabinoid system provides a rationale for considering the medical benefits of marijuana. 5 In addition to reducing pain, there may be effects on nausea, vomiting, gastrointestinal tract motility, and inflammation. 6 These benefits, however, have not been tested empirically and must be weighed against the risks of regular marijuana use in adolescence with potential adverse effects including risk for addiction, 7 lower educational performance, 8 and psychiatric disorders such as schizophrenia. 8 There are no studies evaluating benefit of marijuana use in pediatric IBD. Three observational studies of about 300 adult participants with IBD 9-11 and 1 study of 37 young adults 18-21 years of age 12 suggest that use of marijuana is associated with subjective relief of symptoms. There are 2 placebo-controlled clinical trials in adults with Crohn's disease. THC cigarettes showed improvement of symptoms but not inflammatory markers compared with placebo, 13 and low dose CBD compared with placebo showed no benefit for Crohn's disease. 14 Aside from subjective responses, there is no evidence supporting disease-modifying, long-term benefits of marijuana for patients with IBD.
In Colorado, medical marijuana card applications surged in 2012 after restrictions were loosened, and recreational marijuana stores opened in 2014. In 2015, 38% of Colorado high school students have tried marijuana, and 21% endorse use in the past month. 15 It is widely available in many forms including edibles, CBD Cannabidiol IBD Inflammatory bowel disease THC Delta-9 tetrahydrocannabinol oils, and smokeable products. 16 Here we report on baseline information for 99 pediatric participants with IBD enrolled in an ongoing study to describe their IBD course and their use patterns. We hypothesized that marijuana use might be common in adolescents with IBD and that users might have higher rates of clinical or perceived medical benefit than nonusers. In addition, we sought to obtain detailed information on use patterns, motivations, and perceptions of benefit and harm.
Methods
We designed a descriptive cross-sectional study of patients with IBD 13-23 years of age treated at Children's Hospital Colorado. All patients with IBD were enrolled into the Improve Care Now (www.improvecarenow.org) network so that standardized clinical data were obtained. 17 Participants were recruited from December 2015 through June 2017 by a research coordinator during their outpatient clinic visit, inpatient admission, or during a visit for medication infusion. Of the 174 potential participants, 19 were still undecided or were still to sign consent at next visit; of the remaining 155, 72% (111 of 155) agreed to enroll (Figure) but 12 were excluded from this analysis because of incomplete data (6 cannabinoid levels pending; 6 did not complete surveys).
Consent was signed by parent or participant if 18 years and over, and assent by participants <18 years of age. Study information was provided in a private setting without the presence of a parent. Information obtained from the electronic medical record included demographic data such as age, sex, race, as well as weight, height, type of IBD, and physician global assessment of disease activity. 18 The physician global assessment is a subjective measure in which the physician assigns a disease status to 1 of 4 categories: inactive, mild, moderate, or severe.
Self-report data on appetite, pain, quality of life, depression, anxiety, and marijuana use were collected and managed using Research Electronic Data Capture (REDCAP) tools. 19 Appetite and pain scores were assessed by a visual analog scale from 0 to 100. 20 Validated questionnaires included IBD specific health-related quality of life as assessed by the Impact III questionnaire (validated for ages 13-17 years), 21 the Generalized Anxiety Disorder-7 scale, which was used to assess anxiety, 22 and questions describing marijuana use reported in other studies. 23 A modified version of the Patient Health Questionnaire-9 was used to assess depression in which question 9 about thoughts of self-harm was removed because our hospital standard of addressing this issue prior to patient leaving the building exceeded our resources. 24 Therefore, the total score is not comparable with other distributions of the Patient Health Questionnaire-9. Questions we developed in other studies to assess use of illicit substances including marijuana were used to describe marijuana use. 23 Motivation for use was assessed using 35 exploratory questions, as binary items (yes/no). These questions were adapted from studies investigating nonmedical opiate prescription use, marijuana and alcohol drinking motives, or created for this study. [25] [26] [27] Some of the questionnaire items were validated previously and others were created for this study. We report on items allocated by consensus among the authors into medical (5 questions) or nonmedical (35 questions). Questions on substance abuse and dependence were derived from the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. 28 Serum levels of THC and CBD were measured at enrollment by a liquid chromatography/mass spectrometry technique. 29 At the time of blood draw, participants were asked about past 6-month marijuana use including quantity, route, date, and time. Participants who endorsed use in the past 6 months and/or who self-reported ever using marijuana were designated "ever-users" in analyses. 
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Statistical Analysis Data were examined for accuracy and the distributional properties of each variable. Many of the results are descriptive, consisting of self-reports of marijuana perceptions and use in adolescents with IBD. We compared the marijuana everuse and never-use groups on demographics; IBD disease characteristics; serum levels for THC, metabolites, and/or CBD; and perceptions of risk with regular marijuana smoking. Groups were compared with independent t tests and c 2 tests; nonparametric equivalents (Mann-Whitney U, Fisher exact tests) were used as appropriate if normality assumptions were violated. Logistic regression adjusting for demographic characteristics that differed significantly between groups were further used to evaluate differences in perceptions of risk from using marijuana regularly between ever-users and never-users. All analyses were conducted in SPSS v 24.0 (IBM Corporation, Armonk, New York) and were based on 2-tailed probability tests with 0.05 significance level.
All participants received a substance abuse resource pamphlet at time of the consent. The study was approved by the Colorado Multiple Institution Review Board.
Results
Of the 99 participants, age range 13-22 years, 63% (62 of 99) had diagnosis of Crohn's disease, 27% (27 of 99), ulcerative colitis, and 10% (10 of 99) indeterminate/unknown colitis, 57% (56 of 99) were male, 83% (82 of 99) had quiescent/ mild disease based on physician global assessment ( Table I) . The 32 participants in the ever-use group were older (mean August 2018
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17.0, SD = 1.9 years) than the 67 in the never-use group (mean 15.9 SD = 2.2 years; P = .011). The ever-and never-use groups were similar for sex, race, disease type, disease activity, and measures of pain, appetite, quality of life, depression, and anxiety. Serum cannabinoids were detected in 50% (16 of 32) of the ever-use group but in none of the never-use group (0 of 67) (P < .001).
For the 32 in the ever-use group, denominators for selfreported data differ because of missing responses and are reported. Thirty of 32 ever-users provided responses to questions about perceptions and motivations, and 29 of 32 provided responses to questions about use patterns. Low to no risk of harm with regular use of marijuana was endorsed by 80% (24 of 30) of ever-users and 25% (16 of 65) of never-users (P < .001; Table I ). After adjusting for age, which significantly differed between groups, ever-users were 10.7 times more likely to perceive low to no risk of harm with regular use of marijuana than never-users (OR = 10.7, P < .001). A 3-group analysis (no use, use 13-<18 years of age, and use 18 years+ of age) identified no additional differences.
Use at least weekly was reported by 52% (15 of 29) , and use at least daily by 31% (9/29). Only 4 reported possession of a medical marijuana registry card ( Table I) .
For questions describing marijuana use, such as source and route of use, participants could select multiple choices if applicable (Table II) . Friends (60%) and dealer/black market (17%) were the most commonly reported sources. One-half or more reported smoking (83%) or consuming edibles (50%) with dabbing (40%) and vaping (30%) also being common.
At least 1 medical reason for use was endorsed by 57% (17 of 30), with 53% (16 of 30) reporting use to relieve physical pain (Table III) . One or more nonmedical recreational or psychological reasons for use were reported by 87% (26 of 30). Most common nonmedical motivations for use were to relax and relieve tension 60% (18 of 30), to feel good 50% (15 of 30), and to have a good time with friends 47% (14 of 30). One or more problems with use was reported by 37% (11 of 30).
These 11 reported on average 3.2 (SD = 2.0) problems (range 1-6). Overall, the most common problem was craving or strong desire to use 20% (6 of 30), followed by needing to use more for same effect 17% (5 of 30) and using larger amount for longer than intended 17% (5 of 30).
Discussion
This study of marijuana use by adolescents and young adults with IBD is from a state with legalized recreational marijuana use for adults and medical marijuana use for all. The principal finding in our study of participants 13-22 years of age with IBD is that 32% had ever used marijuana and 9% used daily or almost daily. Furthermore, a substantial proportion reported use for medicinal purpose, use by methods besides smoking, and perceived low risk with regular use. The detection of serum cannabinoids only in the ever-users is consistent with truthful reporting.
Our study confirms that marijuana is easily accessible and is consistent with estimates that rates of use among Colorado high school students have had no statistical change from 2005 to present. 15 Although a medical reason for use was reported frequently, only 4 had a medical marijuana card and friends and family were the most common source. An increasingly larger percentage of adolescents in Colorado 30 and nationally 16 perceives safety with regular marijuana use. In our study, 80% of users perceived low risk of harm with regular marijuana use. The National Academy of Sciences has concluded that there is an association between marijuana use frequency during adolescence and progression to developing problem marijuana use. 2 Risks of high frequency use include motor vehicle collision 6 and fatality 24 if driving while intoxicated; drug dependence with higher rates of anxiety, depression, and psychotic disorders 31 ; use of other drugs 32 ; and psychosocial decline (worsening performance on neuropsychological tests). 33 There is a need for further understanding of the potential medical benefits of marijuana use in IBD.
We found that the most common reasons for using marijuana were to relax and relieve tension, relieve pain, and feel good. Our study did not identify differences between everusers and never-users for clinical measures of IBD severity, quality of life, anxiety, or depression. Theoretically, a different study design such as a randomized controlled trial of marijuana use or placebo could better evaluate the safety and benefit of frequent marijuana use for induction or maintenance of remission, for severe cases, and for those who discontinue established therapies in favor of marijuana alone or marijuana in combination with complementary therapies. 34 However, human subject research involving cannabis remains uniquely challenging because cannabis is a schedule 1 drug under federal law. 3 Route of use of marijuana by participants with IBD may also be a factor in efficacy and safety. The majority in our study smoke marijuana, like most surveys. However, other routes of use were quite common, with 50% of users reporting ingesting marijuana as an edible. Edible marijuana products have been marketed broadly 35 and are popular 36 in Colorado. In addition, there is a perception in the community that high CBD content edibles or oils are beneficial for the treatment of chronic diseases such as IBD 37 and pediatric epilepsy. 38, 39 Dabbing and vaping were reported by 40% and 30% of users in our study. Dabbing is a newly popularized form of self-administering high concentrations of THC with a rapid onset of psychoactive effect. Of concern is that users may have higher rates of tolerance and withdrawal, which are symptoms of addiction and dependence. 40 Understanding use of dab, oil, vape, and other new forms of marijuana products requires ongoing study.
A limitation of this study is that a large proportion of participants (80%) had inactive or mild disease, making it difficult to ascertain a difference in disease activity between groups. Another limitation is the relatively small total number of participants with IBD who endorse use of marijuana. For this reason, we grouped patients with Crohn's disease and patients with ulcerative colitis together. The only other study of marijuana use by a pediatric gastroenterology group enrolled about one-half as many and included only young adults 18-22 years old receiving infliximab infusions. 12 This study found that 70% had used marijuana and one-half did so for medicinal purposes. Additional limitations include that our study did not distinguish between primarily CBD or primarily THC, forms that may have very different biologic effects, 41 and we did not assess adherence rates to prescribed IBD therapies.
There is no appropriate comparison group for our study. The age distribution of our patients (13-22 years old with mean age of users being 17.0 years) overlaps, but is not the same as the population-based studies that categorize by being in high school in Colorado 15 or being in the 12th grade in the US. 16 Each of these surveys used different methods for defining frequency of use. Furthermore, none of these studies assessed motivation for medicinal use of marijuana and no standardized tool exists, so we developed our own tool. Needing to use more marijuana than you used to in order to get the same effect
(17%)
Over-doing it: using a larger amount of marijuana or using marijuana for more time than intended Very little is known about the potential interaction of marijuana with medications used to treat IBD. Cannabinoid metabolism primarily involves the human liver microsomes CYP2C and CYP3A. 42 Tacrolimus, sometimes used to treat severe IBD, 43 also shares this pathway. The use of marijuana may potentially increase the risk of tacrolimus toxicity, possibly because of altered gut absorption as well as inhibition of CYP2C 44 and CYP3A 45 clearance of tacrolimus. In conclusion, our study describes the use of marijuana by adolescents and young adults with IBD. Notably 32% have ever used and 9% are using daily or almost daily. The 9% daily or near daily use is clinically important to recognize and to screen for problems with use. Use for medicinal purposes was frequent, and a substantial proportion reported medicinal benefit; they perceived use as safe and beneficial. An additional phenomena that we observed is that in a state with legal pathways to medical and recreational marijuana, users were self-administering marijuana through multiple modalities including vaping, edibles, and oils besides the more traditional route of smoking. These different routes of administration potentially have different effects on the gastrointestinal system. We believe that marijuana use in adolescents and young adults with IBD is prevalent enough to warrant developing guidelines for periodic screening, testing, and counseling. ■ 
